

Association of Baseline HbA1c with Cardiovascular and Renal Outcomes

Analyses from DECLARE-TIMI 58

Online only supplementary material

Supplementary Table 1 – Baseline characteristics – overall population

Supplementary Table 2 – Baseline characteristics – ASCVD population

Supplementary Table 3 – Baseline characteristics – MRF population

Supplementary figure 1 – Cardiovascular outcomes with dapagliflozin vs. placebo

Supplementary figure 2 - Cardiovascular and renal outcomes with dapagliflozin vs. placebo in the ASCVD population

Supplementary figure 3 - Cardiovascular and renal outcomes with dapagliflozin vs. placebo in the MRF population

Supplementary figure 4 - HbA1c changes with dapagliflozin vs. placebo by baseline HbA1c category

Supplementary Table 1 – Baseline characteristics – overall population

	<7%	7-<8%	8-<9%	>=9%	P-trend
	N=1547	N=6626	N=4520	N=4461	
Age, years, median (IQR)	66.0 (61.0-70.0)	65.0 (60.0-69.0)	64.0 (60.0-68.0)	62.0 (58.0-66.0)	<0.0001
Female sex, N(%)	542 (35.0)	2393 (36.1)	1725 (38.2)	1759 (39.4)	<0.0001
BMI, kg/m ² , median (IQR), N	31.5 (28.1-35.3), 1544	31.2 (27.7-35.2), 6624	31.4 (27.9-35.5), 4518	31.3 (27.7-35.7), 4459	0.7928
Diabetes duration, years, median (IQR), N	9.0 (5.0-14.0)	10.0 (6.0-16.0), 6625	11.0 (7.0-17.0)	11.0 (7.0-17.0), 4460	<0.0001
Risk Category - ASCVD, N (%)	653 (42.2)	2619 (39.5)	1784 (39.5)	1918 (43.0)	0.0330
History of heart failure, N (%)	127 (8.2)	608 (9.2)	446 (9.9)	543 (12.2)	<0.0001
Systolic BP, mmHg, median (IQR)	134.0 (123.5, 144.5)	135.0 (124.5, 145.0)	135.0 (124.0, 145.0)	135.0 (124.0, 145.0)	0.8696
Current smoker	188 (12.2)	918 (13.9)	663 (14.7)	729 (16.3)	<0.0001
Total Cholesterol, median, (IQR), N	156.0 (134.0-183.0), 1529	160.0 (136.0-189.0), 6552	165.0 (138.0-196.0), 4476	171.0 (143.0-205.0), 4411	<0.0001
eGFR, median (IQR), ml/min/1.73m ² , N	84.0 (71.0-93.0)	87.0 (73.0-95.0)	89.0 (76.0-97.0)	92.0 (78.0-99.0), 4460	<0.0001
eGFR, <60 ml/min/1.73m ² , N (%)	119 (7.7)	503 (7.6)	325 (7.2)	317/4460 (7.1)	0.2657
eGFR, 60-90 ml/min/1.73m ² , N (%)	876 (56.6)	3240 (48.9)	1984 (43.9)	1630/4460 (36.5)	<.0001
eGFR, ≥90 ml/min/1.73m ² , N (%)	552 (35.7)	2883 (43.5)	2211 (48.9)	2513/4460 (56.3)	<.0001
Insulin, N (%)	329 (21.3)	2256 (34.0)	2079 (46.0)	2345 (52.6)	<0.0001
Metformin, N (%)	1294 (83.6)	5495 (82.9)	3726 (82.4)	3548 (79.5)	<0.0001
Sulfonylurea, N (%)	531 (34.3)	2761 (41.7)	2060 (45.6)	1968 (44.1)	<0.0001
DPP-4 Inhibitors, N (%)	282 (18.2)	1179 (17.8)	780 (17.3)	646 (14.5)	<0.0001
Beta blockers, N (%)	845 (54.6)	3501 (52.8)	2352 (52.0)	2330 (52.2)	0.1357
ACEI/ARB, N (%)	1262 (81.6)	5488 (82.8)	3672 (81.2)	3526 (79.0)	<0.0001
Statin, N (%)	1241 (80.2)	5042 (76.1)	3323 (73.5)	3147 (70.5)	<0.0001
Anti-platelet, N (%)	988 (63.9)	4064 (61.3)	2752 (60.9)	2679 (60.1)	0.0159

Legend – ASCVD – Atherosclerotic cardiovascular disease, BP – Blood pressure

Supplementary Table 2 – Baseline characteristics – ASCVD population

	<7%	7-<8%	8-<9%	>=9%	P-trend
	N = 653	N = 2619	N = 1784	N = 1918	
Age, years, median (IQR)	65.0 (60.0, 70.0)	64.0 (58.0, 69.0)	63.0 (58.0, 68.0)	61.0 (55.0, 66.0)	<.0001
Female sex, N (%)	151 (23.1)	693 (26.5)	512 (28.7)	593 (30.9)	<.0001
BMI, kg/m ² , median (IQR), N	31.3 (28.0, 35.2), 650	31.0 (27.7, 35.0), 2617	31.3 (28.0, 35.5), 1783	31.7/ (28.1, 36.0), 1917	0.0008
Diabetes duration, years, median (IQR), N	9.0 (5.0, 15.0)	10.0 (5.0, 16.0), 2618	11.0 (6.0, 18.0)	11.0 (6.0, 17.0), 1917	<.0001
History of heart failure, N (%)	87 (13.3)	403 (15.4)	292 (16.4)	374 (19.5)	<.0001
Systolic BP, mmHg, median (IQR)	134.0 (122.5, 145.0)	134.5 (124.0, 145.5)	132.8 (122.5, 144.0)	132.5 (122.5, 143.5)	0.0284
Current smoker	76 (11.6)	375 (14.3)	264 (14.8)	319 (16.6)	0.0019
Total Cholesterol, median, (IQR), N	148.0 (127.0, 175.0), 641	151.0 (129.0, 180.0), 2586	155.0 (129.0, 187.0), 1767	162.0 (136.0, 196.0), 1894	<.0001
eGFR, median (IQR), ml/min/1.73m ² , N	84.0 (70.0, 93.0)	86.0 (72.0, 95.0)	88.0 (73.0, 97.0)	91.0 (76.0, 100.0)	<.0001
eGFR, <60 ml/min/1.73m ² , N (%)	57 (8.7)	258 (9.9)	160 (9.0)	168 (8.8)	0.4189
eGFR, 60-90 ml/min/1.73m ² , N (%)	364 (55.7)	1250 (47.7)	802 (45.0)	722 (37.6)	<.0001
eGFR, ≥90 ml/min/1.73m ² , N (%)	232 (35.5)	1111 (42.4)	822 (46.1)	1028 (53.6)	<.0001
Insulin, N (%)	156 (23.9)	987 (37.7)	923 (51.7)	1126 (58.7)	<.0001
Metformin, N (%)	543 (83.2)	2086 (79.6)	1391 (78.0)	1424 (74.2)	<.0001
Sulfonylurea, N (%)	222 (34.0)	1026 (39.2)	747 (41.9)	766 (39.9)	0.0223
DPP-4 Inhibitors, N (%)	124 (19.0)	421 (16.1)	307 (17.2)	266 (13.9)	0.0063
Beta blockers, N(%)	498 (76.3)	1887 (72.1)	1282 (71.9)	1402 (73.1)	0.5383
ACEI/ARB, N (%)	535 (81.9)	2189 (83.6)	1465 (82.1)	1546 (80.6)	0.0435
Statin, N (%)	582 (89.1)	2279 (87.0)	1526 (85.5)	1620 (84.5)	0.0008
Anti-platelet, N (%)	580 (88.8)	2285 (87.2)	1536 (86.1)	1634 (85.2)	0.0073

Legend – ASCVD – Atherosclerotic cardiovascular disease, BP – Blood pressure


Supplementary Table 3 – Baseline characteristics – MRF population

	<7%	7-<8%	8-<9%	>=9%	P-trend
	N=894	N=4007	N=2376	N=2543	
Age, years, median (IQR)	66.0 (62.0, 70.0)	65.0 (61.0, 69.0)	64.0 (61.0, 68.0)	63.0 (60.0, 67.0)	<.0001
Female sex, N (%)	391 (43.7)	1700 (42.4)	1213 (44.3)	1166 (45.9)	0.0180
BMI, kg/m ² , median (IQR), N	31.7 (28.2, 35.6)	31.3 (27.8, 35.3)	31.5 (27.9, 35.6), 2735	31.0 (27.5, 35.4), 2542	0.0139
Diabetes duration, years, median (IQR), N	8.0 (5.0, 13.0)	10.0 (6.0, 15.0)	11.0 (7.0, 17.0)	11.0 (7.0, 17.0)	<.0001
History of heart failure, N (%)	40 (4.5)	205 (5.1)	154 (5.6)	169 (6.6)	0.0028
Systolic BP, mmHg, median (IQR)	133.8 (124.5, 144.0)	135.0 (125.0, 145.0)	136.0 (125.3, 145.5)	136.0 (125.0, 145.0)	0.0203
Current smoker	112 (12.5)	543 (13.6)	399 (14.6)	410 (16.1)	0.0009
Total Cholesterol, median, (IQR), N	162.0 (140.0, 188.0), 888	166.0 (142.0, 194.0), 3966	171.0 (144.0, 200.0), 2709	176.0 (149.0, 210.0), 2517	<.0001
eGFR, median (IQR), ml/min/1.73m ² , N	84.0 (72.0, 93.0)	87.0 (75.0, 95.0)	90.0 (77.0, 97.0)	92.5 (80.0, 98.0), 2542	<.0001
eGFR, <60 ml/min/1.73m ² , N (%)	62 (6.9)	245 (6.1)	165 (6.0)	149 (5.9), 2542	0.3451
eGFR, 60-90 ml/min/1.73m ² , N (%)	512 (57.3)	1990 (49.7)	1182 (43.2)	908 (35.7), 2542	<.0001
eGFR, ≥90 ml/min/1.73m ² , N (%)	320 (35.8)	1772 (44.2)	1389 (50.8)	1485 (58.4), 2542	<.0001
Insulin, N (%)	173 (19.4)	1269 (31.7)	1156 (42.3)	1219 (47.9)	<.0001
Metformin, N (%)	751 (84.0)	3409 (85.1)	2335 (85.3)	2124 (83.5)	0.3271
Sulfonylurea, N (%)	309 (34.6)	1735 (43.3)	1313 (48.0)	1202 (47.3)	<.0001
DPP-4 Inhibitors, N (%)	158 (17.7)	758 (18.9)	473 (17.3)	380 (14.9)	0.0004
Beta blockers, N (%)	347 (38.8)	1614 (40.3)	1070 (39.1)	928 (36.5)	0.0131
ACEI/ARB, N (%)	727 (81.3)	3299 (82.3)	2207 (80.7)	1980 (77.9)	<.0001
Statin, N (%)	659 (73.7)	2763 (69.0)	1797 (65.7)	1527 (60.0)	<.0001
Anti-platelet, N (%)	408 (45.6)	1779 (44.4)	1216 (44.4)	1045 (41.1)	0.0063

Legend – ASCVD – Atherosclerotic cardiovascular disease, BP – Blood pressure

Supplementary figure 1


Cardiovascular outcomes with dapagliflozin vs. placebo



Legend: CVD – Cardiovascular death


Supplementary figure 2

Cardiovascular and renal outcomes with dapagliflozin vs. placebo in the ASCVD population



Supplementary figure 3

Cardiovascular and renal outcomes with dapagliflozin vs. placebo in the MRF population



Supplementary figure 4

HbA1c changes with dapagliflozin vs. placebo by baseline HbA1c category

